Valeant auc­tions off Den­dreon, skin­care as­sets; Bay­er to col­lab­o­rate with the Uni­ver­si­ty of Pitts­burgh

• A trou­bled Valeant has struck a deal to sell Den­dreon and its prostate can­cer vac­cine Provenge to Chi­na’s San­pow­er Group for $820 mil­lion. Valeant plans to pay down debt with the deal. Adding to the haul, Valeant is al­so sell­ing skin­care brands Cer­aVe, Ac­ne­Free and AM­BI. The phar­ma com­pa­ny still has a long way to go, though, as it stares down $30 bil­lion in debt.

Bay­er is ty­ing up with the Uni­ver­si­ty of Pitts­burgh on a “mas­ter col­lab­o­ra­tion agree­ment” to ad­vance re­search for heart, lung and blood dis­ease in­di­ca­tions. This part­ner­ship cov­ers ear­ly-stage re­search, drug de­vel­op­ment and big da­ta analy­sis in­clud­ing re­al-world ev­i­dence stud­ies. Bay­er is al­so back­ing an in­de­pen­dent in­ves­ti­ga­tor-ini­ti­at­ed clin­i­cal tri­al in sick­le cell dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.